SCHEMBL7900592

SCHEMBL7900592

C[C@H](NC(=O)C1(c2ccccc2)CCN(C(=O)c2ccc(-c3ccc(F)cc3)cc2)CC1)c1ccc(Cl)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY1R P25929 2/20 0.45
SLC6A4 P31645 2/20 0.45
TACR1 P25103 1/20 0.45
KCNH2 Q12809 1/20 0.45
CACNA1H O95180 3/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
SLC6A7 Q99884 1/20 0.43
GRIN2B Q13224 1/20 0.43
HSP90AA1 P07900 1/20 0.43
ALDH1A1 P00352 1/20 0.42
NPC1 O15118 1/20 0.42
MGLL Q99685 2/20 0.42
HSD11B1 P28845 1/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
CA14 Q9ULX7 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL378834 0.95 TACR1 (0.48) NPY1RSLC6A4TACR1MEN1KMT2A
SCHEMBL3714839 0.93 NPC1 (0.49) NPY1RSLC6A4TACR1MEN1KMT2A
SCHEMBL13092254 0.90 KIT (0.44) NPY1RSLC6A4TACR1MEN1KMT2A
SCHEMBL7909164 0.87 POLB (0.50) MEN1KMT2AALDH1A1CA12CA1
SCHEMBL7899549 0.86 CYP1A2 (0.53) NPY1RSLC6A4TACR1KCNH2MEN1
SCHEMBL13092262 0.85 ALDH1A1 (0.47) NPY1RSLC6A4TACR1MEN1KMT2A
SCHEMBL7910160 0.84 KMT2A (0.48) MEN1KMT2ASLC6A7HSD11B1CA12
SCHEMBL13092229 0.84 CA12 (0.48) NPY1RMEN1KMT2AALDH1A1NPC1
SCHEMBL378735 0.84 NPY1R (0.52) NPY1RSLC6A4TACR1KCNH2KMT2A
SCHEMBL13092247 0.84 MGLL (0.44) NPY1RSLC6A4TACR1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
WO-2010106081-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 NPY1R 298/4885SLC6A4 94/4885TACR1 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.